Vaccine seasonality to weigh on Sanofi in third quarter
Sanofi expects a 2% sales boost from favorable currency effects in Q3 2026, but anticipates a 10-15% decline in vaccine sales due to seasonality. The decline is attributed to delayed influenza vaccine deliveries and increased competition for its RSV vaccine, Beyfortus. The company's full-year vaccine sales are expected to decline slightly.
How this was made
The 30-second read
Why it matters
The guidance suggests lower near‑term revenue, which could weigh on the stock ahead of the earnings call.
Market read
Guidance on a major revenue segment for a large European pharma company, relevant for short‑term positioning before earnings.
What to watch
Positive currency effect (+2% sales, +1% EPS) may offset part of the sales decline.
Background
Sanofi released an information note ahead of its Q3 earnings, highlighting a temporary vaccine sales dip due to influenza strain timing and competition for its RSV antibody.
Ticker impact
Sanofi forecasts a 10-15% drop in vaccine sales for Q3 2026, indicating seasonal weakness before its earnings release on Oct 30.
likely downside as investors price in the vaccine sales decline
The new guidance is the first disclosure of a material sales contraction; markets typically react negatively to lower vaccine revenue expectations.
Market effects
Vaccine and broader pharma sector may see heightened scrutiny on seasonal demand patterns.
European pharma stocks could face pressure as Sanofi is a market leader.
Limited to investors tracking major pharma earnings and vaccine demand trends.
Counterpoint
If the seasonal dip is temporary, the stock could rebound once Q4 vaccine sales materialize.
Key entities
- CompanySanofi
French pharmaceutical group issuing the guidance.
